{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Recurrent+and+Metastatic+Breast+Cancer", "query": { "condition": "Locally Recurrent and Metastatic Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 150, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Recurrent+and+Metastatic+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:14:13.894Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03584009", "title": "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 103, "start_date": "2018-09-06", "completion_date": "2021-05-06", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03584009" }, { "nct_id": "NCT00370552", "title": "A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg", "type": "DRUG" }, { "name": "Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg", "type": "DRUG" }, { "name": "Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2007-03", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 6, "location_summary": "Burbank, California • La Verne, California • San Francisco, California + 3 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00370552" }, { "nct_id": "NCT02340221", "title": "A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taselisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 631, "start_date": "2015-04-09", "completion_date": "2021-06-29", "has_results": true, "last_update_posted_date": "2022-07-12", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 16, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02340221" }, { "nct_id": "NCT01740336", "title": "A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0941", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 183, "start_date": "2013-02-06", "completion_date": "2015-12-10", "has_results": false, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 47, "location_summary": "Sedona, Arizona • Anaheim, California • Encinitas, California + 43 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740336" }, { "nct_id": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "abemaciclib", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1035, "start_date": "2025-01-06", "completion_date": "2037-12-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760637" }, { "nct_id": "NCT00559507", "title": "Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "Male Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-10", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2014-04-30", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559507" }, { "nct_id": "NCT00645177", "title": "Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "ABT-869", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Placebo for ABT-869", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2008-07", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-01-29", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 2, "location_summary": "San Francisco, California • Harvey, Illinois", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645177" }, { "nct_id": "NCT02684032", "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2016-06-14", "completion_date": "2022-01-19", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684032" }, { "nct_id": "NCT00066547", "title": "Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "monoclonal antibody HuHMFG1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066547" }, { "nct_id": "NCT02311933", "title": "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Endoxifen Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2015-05-28", "completion_date": "2027-02-02", "has_results": true, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-22T04:14:13.894Z", "location_count": 561, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311933" } ] }